Zobrazeno 1 - 10
of 375
pro vyhledávání: '"Stephen Chia"'
Autor:
Tulin Cil, Jean-François Boileau, Stephen Chia, MJ DeCoteau, Katarzyna J. Jerzak, Anne Koch, Nancy Nixon, May Lynn Quan, Amanda Roberts, Christine Brezden-Masley
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 1774-1802 (2024)
On 15–16 June 2023, healthcare professionals and breast cancer patients and advocates from across Canada met in Toronto, Ontario, for the 2023 Canadian Breast Cancer Symposium (CBSC.). The CBSC. is a national, multidisciplinary event that occurs ev
Externí odkaz:
https://doaj.org/article/7f071540a3ee4962a10266cf3a8e5110
Autor:
Jan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, Stephen Chia, Shane Shapera, Micheal McInnis, Daniel Rayson, Jamil Asselah
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 8019-8038 (2023)
Ongoing advances in precision cancer therapy have increased the number of molecularly targeted and immuno-oncology agents for a variety of cancers, many of which have been associated with a risk of pulmonary complications, among the most concerning b
Externí odkaz:
https://doaj.org/article/326b83ae6cc04c08964475354e707914
Autor:
Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 5050-5053 (2023)
We appreciate the opportunity to respond to the comment [...]
Externí odkaz:
https://doaj.org/article/ec2922d259024378bc8588c63bddf687
Autor:
Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9891-9895 (2022)
The addition of pertuzumab to neoadjuvant trastuzumab and chemotherapy for women with early-stage, high-risk, HER2+ breast cancer has been observed to lead to higher pathologic complete response rates (pCR), and improved event-free survival compared
Externí odkaz:
https://doaj.org/article/8328144413f246ccbb85b8ba358777b4
Autor:
Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer. Ne
Externí odkaz:
https://doaj.org/article/73d02bee3f9e4dc6a76bef48c3ed8ce0
Autor:
Peter Eirew, Ciara O’Flanagan, Jerome Ting, Sohrab Salehi, Jazmine Brimhall, Beixi Wang, Justina Biele, Teresa Algara, So Ra Lee, Corey Hoang, Damian Yap, Steven McKinney, Cherie Bates, Esther Kong, Daniel Lai, Sean Beatty, Mirela Andronescu, Elena Zaikova, Tyler Funnell, Nicholas Ceglia, Stephen Chia, Karen Gelmon, Colin Mar, Sohrab Shah, Andrew Roth, Alexandre Bouchard-Côté, Samuel Aparicio
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Gene fitness and essentiality analyses using in vivo cancer models are challenging due to multiple confounders. Here, the authors develop a quantitative approach to study CRISPR-transduced patient-derived xenografts, which they use to analyse in vivo
Externí odkaz:
https://doaj.org/article/5fd8470d7bc644e19c6718168d7a7669
Publikováno v:
Current Oncology, Vol 29, Iss 7, Pp 4748-4767 (2022)
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we
Externí odkaz:
https://doaj.org/article/c2771e0882234a8db6deadabc902dee0
Autor:
Mehrnoosh Pauls, Stephen Chia
Publikováno v:
Current Oncology, Vol 29, Iss 7, Pp 5139-5149 (2022)
Breast cancer (BC) is the most common malignancy among women in Canada. Adjuvant treatment in early BC can reduce the risk of BC recurrence. Historically, the decision for adjuvant chemotherapy for early BC was made only based on clinical and tumour
Externí odkaz:
https://doaj.org/article/01d9e4d9d050437180911fffbd4a1f2b
Autor:
Serena Di Cosimo, Chiara M. Ciniselli, Sara Pizzamiglio, Vera Cappelletti, Marco Silvestri, Sarra El-Abed, Miguel Izquierdo, Mohammed Bajji, Paolo Nuciforo, Jens Huober, David Cameron, Stephen Chia, Henry L. Gomez, Marilena V. Iorio, Andrea Vingiani, Giancarlo Pruneri, Paolo Verderio
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
BackgroundThe absence of breast cancer cells in surgical specimens, i.e., pathological complete response (pCR), is widely recognized as a favorable prognostic factor after neoadjuvant therapy. In contrast, the presence of disease at surgery character
Externí odkaz:
https://doaj.org/article/f0877e2ca68b49758660451e0fb47a28
Autor:
Angela S. Mathews, Ashley Paul, Irene S. Yu, Colleen McGahan, Eric Bhang, Diego Villa, Karen Gelmon, Antonio Avina-Zubieta, Alina S. Gerrie, Ursula Lee, Stephen Chia, Ryan R. Woods, Jonathan M. Loree
Publikováno v:
Heliyon, Vol 8, Iss 12, Pp e12140- (2022)
Objective: We evaluated survival outcomes for patients with cancer and COVID-19 in this population-based study. Methods: A total of 631 patients who tested positive for severe acute respiratory syndrome coronavirus 2 and were seen at BC Cancer betwee
Externí odkaz:
https://doaj.org/article/8252bc540db744ebbf315444592401bb